To the Editor: According to the retrospective analysis of KRAS genotypes and outcome after treatment with cetuximab in patients with chemotherapy-refractory metastatic colon cancer, Dr De Roock and colleagues reported that patients with KRAS codon p.G13D mutations who received cetuximab compared with best supportive care experienced longer progression-free and overall survival.1 In contrast, patients with other KRAS mutations did not appear to benefit from cetuximab. Previously, any type of KRAS mutation indicated a lack of effect of anti-epidermal growth factor receptor monoclonal antibody therapy.1
Shitara K, Yokota T, Muro K. KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA. 2011;305(6):564–566. doi:10.1001/jama.2011.85
Customize your JAMA Network experience by selecting one or more topics from the list below.